𝔖 Bobbio Scriptorium
✦   LIBER   ✦

107 Efficacy and safety of antiviral therapy in liver transplant recipients with chronic hepatitis C

Book ID
117373619
Publisher
Elsevier Science
Year
2005
Tongue
English
Weight
260 KB
Volume
42
Category
Article
ISSN
0168-8278

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Efficacy, predictors of response, and po
Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C
✍ Marina Berenguer; Antonio Palau; Alberto Fernandez; Salvador Benlloch; Victoria πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 110 KB πŸ‘ 1 views

There are unresolved issues regarding sustained virological response (SVR), tolerance and risk of rejection following antiviral therapy in liver transplantation (LT). The aim of our study was to determine efficacy, rejection risk and factors associated with SVR. HCV-infected LT patients with at leas

Worse recent efficacy of antiviral thera
Worse recent efficacy of antiviral therapy in liver transplant recipients with recurrent hepatitis C: Impact of donor age and baseline cirrhosis
✍ Marina Berenguer; Victoria Aguilera; MartΓ­n Prieto; Cecilia Ortiz; Maria RodrΓ­gu πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 109 KB πŸ‘ 1 views

We hypothesized that antiviral efficacy [sustained virologic response (SVR)] has improved in recent years in the transplant setting. Our aim was to assess whether the efficacy of pegylated interferon (PegIFN)-ribavirin (Rbv) has improved over time. One hundred seven liver transplant patients [74% me

Long-term histological effects of preemp
Long-term histological effects of preemptive antiviral therapy in liver transplant recipients with hepatitis C virus infection
✍ Alexander Kuo; Vivian Tan; Billy Lan; Mandana Khalili; Sandy Feng; John P. Rober πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 197 KB

The long-term effects of preemptive antiviral therapy on fibrosis progression in liver transplant recipients with hepatitis C virus (HCV) were examined in a cohort of consecutive liver transplant recipients who received preemptive antiviral therapy for 48 weeks (95% were virologic nonresponders). Co